Want to see AU:BLS full AI Analyst Report?
BLS Stock Chart & Stats
AU$0.04
<AU$0.01(4.17%)
At close: 4:00 PM EST
AU$0.04
<AU$0.01(4.17%)
Day’s Range― - ―
52-Week RangeAU$0.33 - AU$1.10
Previous CloseN/A
VolumeN/A
Average Volume (3M)4.35M
Market Cap
AU$206.19M
Enterprise ValueAU$228.67M
Total Cash (Recent Filing)AU$7.60M
Total Debt (Recent Filing)AU$7.43M
Price to Earnings (P/E)23.1
Beta1.56
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding229,103,590
10 Day Avg. Volume2,483,521
30 Day Avg. Volume4,348,514
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)7.54
Price to Sales (P/S)2.90
P/FCF Ratio22.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained high revenue growth indicates expanding product adoption and market penetration in the medicinal cannabis segment. Over 2–6 months this supports scale advantages, stronger bargaining power with channels, and the ability to invest in capacity or new product commercialization.
Profitability MarginsHealthy operating and net margins show the company can convert sales into profit despite competitive pressures. Margin durability supports reinvestment capacity, resilience to cost swings, and the potential to sustain R&D or commercial expansion without eroding core profitability.
Balance Sheet & Cash GenerationConservative leverage and a dramatic improvement in cash generation materially strengthen financial flexibility. Strong cash conversion reduces refinancing risk, enables capex or M&A funding from operations, and supports durability through industry cycles over the medium term.
Bears Say
Gross Margin PressureA mid-30s gross margin limits the cushion to absorb rising input or compliance costs in cultivation and processing. Without structural margin expansion through productivity or pricing, profitability is more exposed to commodity-like cost swings and competitive discounting.
Limited Operating ScaleA very small workforce suggests constrained in-house capacity for manufacturing, quality control, and commercial roll-out. Long-term growth may depend on outsourcing or partnerships, which can compress margins and slow response times in scaling regulated production.
Regulatory And Market DependenceRevenue and market access rely heavily on regulatory approvals and prescribing trends. These structural dependencies can delay product launches, limit market expansion, and create persistent revenue uncertainty until approvals and reimbursement pathways are firmly established.
BLS FAQ
What was Bioxyne Limited’s price range in the past 12 months?
Bioxyne Limited lowest share price was AU$0.33 and its highest was AU$1.10 in the past 12 months.
What is Bioxyne Limited’s market cap?
Bioxyne Limited’s market cap is AU$206.19M.
When is Bioxyne Limited’s upcoming earnings report date?
Bioxyne Limited’s upcoming earnings report date is Aug 28, 2026 which is in 45 days.
How were Bioxyne Limited’s earnings last quarter?
Currently, no data Available
Is Bioxyne Limited overvalued?
According to Wall Street analysts Bioxyne Limited’s price is currently Overvalued.
Does Bioxyne Limited pay dividends?
Bioxyne Limited does not currently pay dividends.
What is Bioxyne Limited’s EPS estimate?
Bioxyne Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioxyne Limited have?
Bioxyne Limited has 229,103,590 shares outstanding.
What happened to Bioxyne Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bioxyne Limited?
Currently, no hedge funds are holding shares in AU:BLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioxyne Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
200.00%
12-Months-Change
Fundamentals
Return on Equity
56.29%
Trailing 12-Months
Asset Growth
131.94%
Trailing 12-Months
Company Description
Bioxyne Limited
Headquartered in Sydney, Australia, Bioxyne Limited is a life sciences and health company established in 1998. The firm dedicates itself to the research, development, marketing, and distribution of nutritional supplements and beauty products. Its operations are divided into wholesale and direct sales segments, reaching customers online, through partners, and directly across the United States and Asia. Bioxyne's diverse product line includes functional foods and cosmetic solutions, notably Progastrim for digestive and immune wellness, Progastrim plus Vitamin C for cold symptom relief, and proTract, specifically formulated for infant eczema (atopic dermatitis).
Technical Analysis
Bubs Australia Ltd.
―
Nuchev Pty Ltd
―
Holista Colltech Limited
―
Nutritional Growth Solutions Ltd.
―
Clover Corporation Limited
―
Options Prices
Currently, No data available
---